BioSpace News Archive

Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, announced today a multi-target discovery collaboration leveraging Valence’s platform for generative drug design with Servier, a global pharmaceutical company.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021.

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform.

Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual global innovation challenge called The Horizon Prize focused on speeding diagnosis and care for people impacted by rare disease

Metagenomi, a metagenomics powered gene editing company, today announced the appointment of biotech industry veteran, Jian Irish, Ph.D. as Chief Operating Officer

Aspen Surgical Products, Inc., a leader in surgical disposable products, announced the acquisition of BlueMed Medical Supplies, Inc..

Biocom California and the California Life Sciences Association (CLSA) today released data analyzing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline.

RSIP Vision, a leading innovator in medical imaging through advanced AI and computer vision solutions, today announces an advanced joint segmentation tool for detailed, non-invasive planning of revision arthroplasty and other orthopedic procedures for patients with pre-existing metal implants

Nascent Biotech, Inc. (OTCQB:NBIO) , a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Companys lead Monoclonal Antibody (Mab) therapeutic asset

Lumenis Ltd, the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, is pleased to announce its formal partnership with the AdventHealth Nicholson Center (Orlando, FL) to create a dedicated Center of Excellence as a medical training program.